Colchicine for Excess ASCVD Risk in IMIDs? Experts Weigh In

Experts assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic cardiovascular disease (ASCVD) in patients with immune-mediated inflammatory diseases (IMIDs).

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Boston ,Massachusetts ,Philadelphia ,Moonlake ,Fresenius Kabi ,Paul Ridker ,Edward Loftus Jr ,Janssen Biologics ,Christie Bartels ,Jamesj Leyden ,Bristol Myers Squibb ,Joel Gelfand ,Eli Lilly ,Celgene Receptos ,Pfizer ,Novartis ,University Of Wisconsin ,Glaxosmithkline ,Genentech ,Boehringer Ingelheim ,Iterative Health ,Drug Administration ,Amgen ,Jack Zarrow Family ,Mayo Clinic ,Veolia North ,Celltrion Healthcare ,Gossamer Bio ,